Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Communications Medicine|June 27, 2024
Differences in metalloproteinases and their tissue inhibitors in the cerebrospinal fluid are associated with deliriumMari Aksnes, Mari Haavig Schibstad, Farrukh Abbas Chaudhry, et al.
BMC Medical Education|October 10, 2024
Co-designing an interprofessional digital education resource on delirium: a student-led approachChristine Brown Wilson, Tara Anderson, Margaret Graham, et al.
BMC Medical Education|December 19, 2024
'The upside-down' healthcare professional students' experiences of delirium: an all-Ireland focus group studyGary Mitchell, Margaret Graham, Jill Murphy, et al.
The Lancet. Neurology|October 23, 2021
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trialPatrick Gavin Kehoe, Nicholas Turner, Beth Howden, et al.
Health Technology Assessment (Winchester, England)|April 11, 2025
Lessons from the PROTECT-CH COVID-19 platform trial in care homesPhilip M Bath, Jonathan Ball, Matthew Boyd, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Brain : a Journal of Neurology|October 23, 2015
Common polygenic variation enhances risk prediction for Alzheimer's diseaseValentina Escott-Price, Rebecca Sims, Christian Bannister, et al.
The Lancet. Microbe|July 6, 2021
Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation studySuzanne Pickering, Rahul Batra, Blair Merrick, et al.
The Journal of Infection|February 11, 2023
HTLV seroprevalence in people using HIV pre-exposure prophylaxis in EnglandDaniel Bradshaw, Arham Khawar, Poorvi Patel, et al.
The New England Journal of Medicine|March 9, 2012
Donepezil and memantine for moderate-to-severe Alzheimer's diseaseRobert Howard, Rupert McShane, James Lindesay, et al.
Pageof 15